Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


C&C Vision

This article was originally published in Start Up

Executive Summary

The options for people suffering from the age-related loss of ability to change eye focus from far to near are few and far from satisfactory. C&C Vision hopes to fill a need in the huge, untapped market of patients that suffer from presbyopia with an accommodating refractive lens.

You may also be interested in...

Allergan Crosses The Last Frontier in Ophthalmology

Ophthalmology companies have long recognized that many people will pay for the benefit of being able to see without wearing glasses. The success of LASIK laser surgery has borne this out, but that market is maturing. Presbyopia, the disorder that causes people to need reading glasses as they get older, isn't helped by laser surgery. It can, however, be helped by intraocular lenses. With Allergan's recent CE approval of an intraocular lens for presbyopia, ophthalmology companies see a new market to capitalize on.

Refractive Surgery

For the ultimate in convenience, hundreds of thousands of nearsighted and farsighted patients are turning to refractive surgery, or surgical vision correction procedures that promise a permanent alternative to glasses. New companies that wish to grab a portion of the $12 billion US market for vision correction are avoiding the crowded and competitive excimer laser business, with technologies that treat patients that LASIK (laser in-situ keratomileusis) doesn't serve well.

NANS 2021: Nevro’s HF10 Spinal-Cord Stimulator Succeeds In Two Trials

SENZA PDN showed Nevro's HF10 spinal cord stimulation therapy provided sustained relief to patients with painful diabetic neuropathy. Results of a separate trial showed HF10 improved outcomes in patients with non-surgical refractory back pain.


Related Companies

Related Deals




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts